Geron Corporation

NASDAQ:GERN

Biotechnology

Healthcare
$0.99 +4.07%

+$0.05 today

Market cap
$638.38M
Beta
0.60
P/E (TTM)
-12.3
EPS (TTM)
-$0.10
52W Low $1.04High $2.01

Volume 34.97M

Average 16.28M

GERN Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Geron CorporationNASDAQ: GERN

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares grows in line with its trailing trend

Q1 FY2026 weighted avg shares of 669.38M shares rose 0.5% year over year, behind the +1.6% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.3% from the prior quarter. Over 3 fiscal years it compounded at +20.5% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +0.5% toward the trailing-twelve-month pace of +1.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
669.38M+0.3% QoQ
Last fiscal yearDec 2025
666.66M+3.2% YoY
LTMMar 2026
667.45M+1.6% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.5%——
1 year+3.2%——
3-year CAGR+20.5%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
666.66M USD
Year-over-year change
+3.2%
4-year CAGR
+19.4%

Weighted Avg Shares vs competitors

How GERN compares with its peers on the latest reported figures

  • GERN's LTM Mar 2026 weighted avg shares of 667.45M shares is the highest of the 8 companies compared; the peer median is 31.26M shares.
  • Its year-over-year change of +1.6% is the 6th highest of 7, against a peer median of +3.4%.
  • Over three fiscal years its annual growth of +20.5% compares with a peer median of +9.1%.
GERN Competitors Peer median
Weighted Avg Shares for GERN and competitors
Company Period LTM YoY 3-year CAGR
GERNGeron CorporationLTM Mar 2026667.45M +1.6%+20.5%
INCYIncyte CorporationLTM Jun 2026198.21M +2.5%-4.2%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026179.3M +96.8%+77.8%
IPSCCentury Therapeutics, Inc.LTM Mar 202686.45M +4.3%+14.4%
ATNMActinium Pharmaceuticals, Inc.LTM Jun 202631.26M +0.3%+8.9%
COAGHemab Therapeutics Holdings, Inc. Common StockFY202527.44M ——
RIGLRigel Pharmaceuticals, Inc.LTM Mar 202618.08M +2.4%+1.4%
DMRADamora Therapeutics, Inc.LTM Mar 20261.33M +9.5%+9.3%
Peer median (excluding GERN) 31.26M+3.4%+9.1%

Competitors are the stored peer set for GERN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.39M596K237K76.99M183.88M
Cost of Revenue0001.26M4.75M
Gross Profit1.39M596K237K75.74M179.14M
Gross Margin100.0%100.0%100.0%98.4%97.4%
Research & Development85.73M95.52M125.05M103.74M73.72M
Selling, General & Admin29.67M43.63M69.14M145.73M159.26M
Operating Expenses115.39M139.15M194.18M249.47M232.97M
Depreciation & Amortization783K868K1.03M1.22M1.2M
EBITDA(111.59M)(134.15M)(174.78M)(154.85M)(51.92M)
EBITDA Margin-8010.7%-22508.6%-73747.7%-201.1%-28.2%
Operating Income(114M)(138.55M)(193.94M)(173.73M)(53.84M)
Operating Margin-8183.7%-23246.6%-81832.9%-225.6%-29.3%
Interest Income527K2.53M18.15M19.61M18.12M
Interest Expense3.74M6.88M8.31M18.5M32.66M
Other Income / Expenses(2.11M)(3.35M)9.82M(840K)(31.95M)
Income Before Tax(116.11M)(141.9M)(184.13M)(174.57M)(85.78M)
Pre-Tax Margin-8335.4%-23808.9%-77690.7%-226.7%-46.7%
Income Tax Expense00000
Net Income(116.11M)(141.9M)(184.13M)(174.57M)(85.78M)
Net Margin-8335.4%-23808.9%-77690.7%-226.7%-46.7%
EPS (Basic)(0.37)(0.37)(0.32)(0.27)(0.13)
EPS (Diluted)(0.37)(0.37)(0.32)(0.27)(0.13)
Weighted Avg Shares327.63M380.78M570.65M646.03M666.66M
Weighted Avg Shares (Diluted)327.63M380.78M570.65M646.03M666.66M

Geron Corporation

NASDAQ:GERN

Intrinsic Alpha fair value

Locked

Current Price

$0.99

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.